Novartis AG (NYSE: NVS) will present data from 10 research abstracts at the European Academy of Allergy and Clinical Immunology Congress in 2026. The presentations will focus on Rhapsido (remibrutinib), the company's BTK inhibitor treatment.

The data includes results from the Phase III RemIND trial examining Rhapsido's effectiveness in chronic inducible urticaria and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria. Two late-breaking oral presentations are scheduled for June 12.

The abstracts cover multiple conditions including chronic spontaneous urticaria, chronic inducible urticaria, and food allergy. One presentation will examine remibrutinib's efficacy and safety in adults with IgE-mediated peanut allergy from a Phase 2 study.

Additional presentations will address patient burden and treatment experiences through real-world evidence studies, including physician perspectives on chronic urticaria care in China and findings from the CURE Registry regarding treatment escalation needs.

The congress presentations are scheduled between June 12-15, with sessions including oral presentations, flash talks, and thematic poster sessions covering various aspects of the treatment and disease management.